May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Potential Adverse Events Associated With Intravitreal Bevacizumab for Retinal and Choroidal Vascular Disease
Author Affiliations & Notes
  • L. J. Wong
    Ophthalmology, The Colorado Health Foundation and the University of Colorado, Denver, Colorado
    Ophthalmology, Stanford University, Stanford, California
  • R. U. Desai
    Ophthalmology, Stanford University, Stanford, California
  • A. Jain
    Ophthalmology, Stanford University, Stanford, California
  • D. Feliciano
    Ophthalmology, Stanford University, Stanford, California
  • D. M. Moshfeghi
    Ophthalmology, Stanford University, Stanford, California
  • S. R. Sanislo
    Ophthalmology, Stanford University, Stanford, California
  • M. S. Blumenkranz
    Ophthalmology, Stanford University, Stanford, California
  • Footnotes
    Commercial Relationships  L.J. Wong, None; R.U. Desai, None; A. Jain, None; D. Feliciano, None; D.M. Moshfeghi, Genentech, C; S.R. Sanislo, Genentech, C; M.S. Blumenkranz, Genentech, C.
  • Footnotes
    Support  Stanford University Medical Scholars
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 254. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      L. J. Wong, R. U. Desai, A. Jain, D. Feliciano, D. M. Moshfeghi, S. R. Sanislo, M. S. Blumenkranz; Potential Adverse Events Associated With Intravitreal Bevacizumab for Retinal and Choroidal Vascular Disease. Invest. Ophthalmol. Vis. Sci. 2008;49(13):254. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose:
 

To systematically study potential adverse events associatedwith the use of intraocular bevacizumab at a single medicalcenter.

 
Methods:
 

Retrospective study of all consecutive patients receiving intraocularbevacizumab injections at the Stanford University Departmentof Ophthalmology between November 15, 2005 and July 14, 2006.Bevacizumab was given for exudative age-related macular degeneration(AMD), retinal vascular occlusion, diabetic macular edema (DME),neovascular glaucoma (NVG), myopic choroidal neovascularization(CNV), von Hippel-Lindau (vHL) disease, and CNV that was idiopathic,trauma-induced, or vasculitis-related.

 
Results:
 

We analyzed medical records of 188 subjects (205 eyes) who receiveda total of 578 injections of 1.25 mg bevacizumab. Follow-uprate was 97%. The average follow-up was approximately 6 months.5 eyes with exudative AMD developed retinal pigment epithelial(RPE) tears, all with pre-existing RPE detachments (RPED’s).These 5 eyes represented 3% of all eyes treated and 7% of theeyes with pre-existing RPED’s at initiation of treatment.No subject experienced thromboembolic complications or death.Other adverse events were rare. Eyes treated for AMD gainedabout 1 line Snellen of visual acuity (p < 0.05).

 
Conclusions:
 

Intraocular bevacizumab appears to be well-tolerated for thetreatment of a variety of retinal and choroidal vascular diseases.RPE tears may occur when treating choroidal neovascularization,particularly in patients with pre-existing RPE detachment.  

 

 
Keywords: age-related macular degeneration • neovascularization • vascular endothelial growth factor 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×